Increasing evidence suggests that IR is at the crossroads of metabolic syndromes (MetS) (e.g., obesity, diabetes mellitus, hypertension, and cardiovascular disease) in humans, affecting insulin-regulated pathways and many organs once IR is elevated (14–17). This evidence concerns the gene INS and diabetes mellitus.